NCT03709082View on ClinicalTrials.gov

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

March 12, 2020

Study Completion Date

February 3, 2021

Conditions
HER2-positive Breast CancerBreast Cancer Metastatic
Interventions
DRUG

Palbociclib 75mg

Oral Administration

DRUG

Letrozole 2.5mg

Oral Adminstration

DRUG

T-DM1

Intravenous Administration

DRUG

Palbociclib 100mg

Oral Administration

DRUG

Palbociclib 125mg

Oral Administration

DRUG

Palbociclib

Oral Administration

Trial Locations (5)

64064

The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit

64154

The University of Kansas Cancer Center, North Clinic, Kansas City

66112

The University of Kansas Cancer Center, West Clinic, Kansas City

66205

The University of Kansas Cancer Center, Westwood Campus, Kansas City

66210

The University of Kansas Cancer Center, Overland Park Clinic, Overland Park

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Kansas Medical Center

OTHER

NCT03709082 - Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter